- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00772070
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
Antibody Responses to a Reduced Dose of Menomune® in Children Who Previously Received an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine, TetraMenD
This study was designed to simulate meningococcal challenge by vaccination with a fractional combined dose of unconjugated meningococcal polysaccharides A, C, Y, and W-135, Menomune® in children who were vaccinated with one dose of TetraMenD at least 18 months earlier.
Primary Objective:
To evaluate and compare the antibody responses to a reduced dose of Menomune® in participants who had previously received a tetravalent meningococcal diphtheria toxoid conjugate vaccine to those responses in participants who received the same reduced dose of Menomune® but had not previously received any meningococcal vaccine.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Arkansas
-
Jonesboro, Arkansas, États-Unis, 72401
-
Little Rock, Arkansas, États-Unis, 72211
-
-
Massachusetts
-
Woburn, Massachusetts, États-Unis, 01801
-
-
Missouri
-
Bridgeton, Missouri, États-Unis, 63044
-
-
New York
-
Rochester, New York, États-Unis, 14620
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15241
-
Sellersville, Pennsylvania, États-Unis, 18960
-
-
Virginia
-
Norfolk, Virginia, États-Unis, 23501
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria :
- Stage I
- Participant is healthy, as determined by medical history and physical examination.
- Participant is at least 3 years of age but not yet 6 years of age at the enrolment.
- For the TetraMenD group: received one dose of TetraMenD as a participant in trial 603-02 no less than 18 months prior to enrolment
- For the Control group: no previous history of any meningococcal vaccination
- Parent/Guardian has signed Institutional Review Board- (IRB-) approved informed consent form.
- Stage II
- Participant is healthy, as determined by medical history and physical examination.
- Participant is at least 3 years of age but not yet 6 years of age at the time of enrollment in Stage 1.
- Enrolled in the Control group only and received one dose of the reduced dose Menomune at Stage 1.
- Parent/Guardian has signed Institutional Review Board- (IRB-) approved informed consent form.
Exclusion Criteria :
- Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric etc.)
- Known or suspected impairment of immunologic function
- Acute medical illness with or without fever within the last 72 hours or an axillary temperature (≥ 99.5ºF [≥ 37.5ºC]) at the time of inclusion
- For Stage I, history of documented invasive meningococcal disease or previous meningococcal vaccination with exception of those participants recruited from Trial 603-02.
- For Stage II, history of documented invasive meningococcal disease or participant did not receive Reduced-dose Menomune® six months prior.
- Administration of immune globulin, other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting < 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
- Antibiotic therapy within the 72 hours prior to vaccination or antibiotic therapy within the 72 hours prior to having any blood sample drawn
- Received any vaccine in the 28-day period prior to study vaccination, or scheduled to receive any vaccination during the 28-day period after study vaccination in Stage 1 of the trial.
- Suspected or known hypersensitivity to any of the vaccine components
- Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures
- Enrolled in another clinical trial
- Any condition, which, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Previously received TetraMenD
Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.
|
0.05 mL, Subcutaneous
Autres noms:
|
Expérimental: Meningococcal vaccine-naїve
Participants have never received a Meningococcal vaccine in the past.
|
0.05 mL, Subcutaneous
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Geometric Mean Titers (GMT) of Serum Bactericidal Activity for Each Vaccine Serogroups Before and Post-vaccination.
Délai: Day 0 and Days 8 and 28 post-vaccination
|
Day 0 and Days 8 and 28 post-vaccination
|
Autres mesures de résultats
Mesure des résultats |
Délai |
---|---|
Percentage of Participants With at Least a 4-fold Rise in Serum Bactericidal Activity to Each Vaccine Meningococcal Serogroups.
Délai: Baseline to Day 8 and Day 28 post-vaccination
|
Baseline to Day 8 and Day 28 post-vaccination
|
Percentage of Participants Reporting Solicited Local and Systemic Reactions Within Days 0 to 7 Post-vaccination.
Délai: Day 0 to 7 post-vaccination
|
Day 0 to 7 post-vaccination
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système nerveux central
- Maladies du système nerveux
- Infections
- Infections bactériennes
- Infections bactériennes et mycoses
- Infections bactériennes à Gram positif
- Infections à Actinomycétales
- Infections à corynébactéries
- Diphtérie
- Méningite
- Effets physiologiques des médicaments
- Facteurs immunologiques
- Vaccins
Autres numéros d'identification d'étude
- MTA17
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
-
Sanofi Pasteur, a Sanofi CompanyComplétéMéningite | Infections méningococciquesÉtats-Unis
-
SanofiComplétéMéningite | Infections méningococciques | Méningite méningococciqueÉtats-Unis
-
Sanofi Pasteur, a Sanofi CompanyComplétéMéningite | Infections méningococciques | Méningite méningococcique | Méningococcie invasiveÉtats-Unis
-
Sanofi Pasteur, a Sanofi CompanyComplétéMéningite | Infections méningococciques | Méningite méningococciqueÉtats-Unis, Porto Rico
-
Sanofi Pasteur, a Sanofi CompanyComplétéMéningite | Infection méningococciqueÉtats-Unis
-
Sanofi Pasteur, a Sanofi CompanyComplétéInfections méningococciques | Méningite méningococciqueÉtats-Unis
-
Sanofi Pasteur, a Sanofi CompanyComplétéMéningite | Infections méningococciques | Méningite méningococciqueÉtats-Unis
-
Sanofi Pasteur, a Sanofi CompanyComplétéMéningite | Infection méningococciqueCanada
-
Sanofi Pasteur, a Sanofi CompanyComplétéMéningite | Infections méningococciques | Méningite méningococciqueFinlande
-
Sanofi Pasteur, a Sanofi CompanyComplétéMéningite | Infections méningococciques | Méningite méningococciqueÉtats-Unis, Porto Rico